Talia Puzantian, PharmD, BCPP

Binge Eating Disorder: Should You Use Vyvanse?

June 1, 2015

Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.com Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Daniel Carlat, MD

Editor-in-Chief, Publisher, The Carlat Report.

Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

In January of this year, the FDA approved the stimulant lisdexamfetamine (Vyvanse) as the first drug with an indication for binge eating disorder (BED). Patients are hearing the buzz and may be asking you to prescribe it, but you may have some questions first.

Vyvanse: A Look at America’s Most Prescribed Stimulant

November 1, 2014

Talia Puzantian, PharmD, BCPP

Why has Vyvanse become by far the most prescribed stimulant in the United States? Great marketing? A great product? Some combination of the two?

Intuniv: Exorbitant, Sedating, and Second-Line

November 1, 2014

Talia Puzantian, PharmD, BCPP

Guanfacine, a drug originally used to treat hypertension, has been reformulated and now has new life as a medication to treat ADHD in children.

Belsomra: A New Hypnotic? Don’t Get Too Excited

October 1, 2014

Talia Puzantian, PharmD, BCPP

Talia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. www.taliapuzantian.com Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

In the wake (pun intended) of last year’s FDA warnings of next-morning impairment and the lower dosing recommendations for “Z drugs,” wouldn’t now be the perfect time for a new hypnotic to enter the marketplace?